

CUMULATIVE INDEX 1993

Volume 13

March	RENAL FUNCTION, pages 1-312
June	NUTRITION SUPPORT, pages 313-530
September	PATHOPHYSIOLOGY OF THYROID DISEASE, pages 531-757
December	ROUTINE HEMATOLOGIC TESTING, pages 759-1021

Note: Page numbers of article and issue titles are in **boldface** type

A MUDPIE mnemonic, in metabolic acidosis, 112

Absorptiometry, in nutritional assessment, 336

Accessory cells, in autoimmune thyroid disease, 690-694

Accreditation programs, 513-514, 988-989

Acid electrophoresis, hemoglobin, 804

Acid elution technique, for fetal hemoglobin detection, 910-912

Acid loading tests, in renal tubular acidosis, 121-122

Acid phosphatase, determination of, prostatic, 279-284

Acid-base status, **103-116**

- buffer regulation of, 104-105
- diagnosis of, anion gap in, 109-110, 112
- blood collection for, 106
- Henderson equation in, 106-107
- pH to hydrogen ion conversion in, 107-108
- prediction of compensatory responses in, 108
- normal parameters of, 103-104
- perturbations in, 110-114. See also *Acidosis; Alkalosis*.
- mixed, 104, 114
- therapy for, 115

principles of, 103-104

systemic response in, 104-106

Acidemia, definition of, 103

Acidosis, definition of, 103-104

- hypophosphatemia in, 195
- lactic, 110

metabolic, diagnosis of, 111-113

hyperchloremic, 109-110, 112-113

hyperkalemic, 150-151

in mixed acid-base disorders, 114

potassium redistribution in, 151-152

renal tubular. See *Renal tubular acidosis*.

respiratory, diagnosis of, 113

- in mixed acid-base disorders, 114
- potassium redistribution in, 152

Acquired immunodeficiency syndrome. See *Human immunodeficiency virus infection*.

Acromegaly, hyperphosphatemia in, 189

Activated partial thromboplastin time, in liver disease, 960

- with lupus anticoagulant, 962-963

Activity coefficient, in vitamin assay, 374

Acute interstitial nephritis, diagnosis of, 92

Acute lymphocytic leukemia, diagnosis of, flow cytometry in, 838-839

Acute mixed lineage leukemias, diagnosis of, flow cytometry in, 840

Acute Physiology and Chronic Health Evaluation system, in outcome prediction, 346-348

Acute tubular necrosis, diagnosis of, 91-92

Adrenal gland, disorders of, hypertension in, 292-297

Adrenocorticotropic hormone, determination of, 295

Age, nutritional assessment in, results interpretation and, 324-325

AIDS (acquired immunodeficiency syndrome). See *Human immunodeficiency virus infection*.

Alanine transaminases, in vitamin assay, 376

Albumin, abnormalities of, detection of, 594-595
 free hormone hypothesis and, 600
 in elderly persons, 348
 in nutritional assessment, 338-339, 345-346, 356-357
 in urine, 14-15
 physicochemical properties of, 586
 variations in, 591-592

Alcoholism, hypophosphatemia in, 199

Aldosterone, deficiency of, hyperkalemia in, 150-151
 excess of, hypertension in, 293-294
 resistance to, hyperkalemia in, 151

Alkalolemia, definition of, 103

Alkaline electrophoresis, hemoglobin, 803-804

Alkalosis, definition of, 103-104
 metabolic, diagnosis of, 113
 in mixed acid-base disorders, 114
 respiratory, diagnosis of, 113-114
 hypocalcemia in, 166
 hypophosphatemia in, 196-197
 in mixed acid-base disorders, 114

Alpha-2-antiplasmin, assays for, 953

1-Alpha-hydroxylase deficiency, hypocalcemia in, 164-165

Aluminum bone disease, hypercalcemia in, 171

Aluminum intoxication, in hyperphosphatemic treatment, 191-192

Amino acids, metabolic diseases of. See also *Phenylketonuria*.
 nutrition support in, 413-415
 requirements of, in elderly persons, 441-442

Ammonium chloride loading test, in renal tubular acidosis, 121-122

Analbuminemia, 592

Anaplastic thyroid carcinoma, 726
 fine-needle aspiration in, 703
 treatment of, 730-731

Anemia, Fanconi's, neutropenia in, 882-883
 hemolytic, diagnosis of, staining for, 912-913
 from infant formulas, 393
 iron deficiency, 395, 443-444
 red cell indices in, 777-781
 wellness testing for, 486-487
 macrocytic, red cell indices in, 781
 megaloblastic, in folic acid deficiency, 376-377
 neutropenia in, 888
 microcytic, differential diagnosis of, red cell indices in, 777-781
 mean platelet volume in, 946-947
 normocytic, red cell indices in, 781
 of prematurity, 395-396

of senescence, 444

Anergy, in malnutrition, 340-341

Anesthesia, lymphocytopenia in, 929

Aneuploidy, measurement of, flow cytometry in, 842, 844

Angioimmunoblastic lymphadenopathy with dysproteinemia, lymphocytopenia in, 927

Angiotensin(s), in renal function, 8

Angiotensin converting enzyme inhibitors, 239-240, 243-244

Anion gap, in acid-base status, 109-110, 112
 urinary, in renal tubular acidosis, 120-121

Anionic dyes, 762

Antacids, hypophosphatemia from, 193

Anthropometry, in nutritional assessment, 333-334

Antibiotics, in neutropenia, 892

Antibodies, anticalorilipin, 963-964
 Factor VIII, 961-962
 in malnutrition, 459

Anticoagulants, acquired circulating, 961-962

Antidiuretic hormone, inappropriate secretion of, hyponatremia in, 138, 142

Anti-DNA antibody measurement, in glomerular disease, 73-75

Antilymphocyte therapy, lymphocytopenia in, 927

Antineutrophil antibodies, in glomerular disease, 79-81
 neutropenia and, 882

Antioxidants, for free radicals. See under *Free radicals*.

Antiphospholipid antibodies, 963-964

Antithrombin III, assays for, 952-953
 deficiency of, 964-965

APACHE (Acute Physiology and Chronic Health Evaluation) system, in outcome prediction, 346-348

Aperture impedance, in red cell analysis, 775

Appendicitis, band count in, 898-899
 lymphocytopenia in, 928

Arachidonic acid metabolites, in kidney function, 241-245
 in renal function, 8-9

Arginine, in urea cycle disease, 430

Arginine hydrochloride loading test, in renal tubular acidosis, 122

Arm circumference, in nutritional assessment, 334

Arteritis, temporal, erythrocyte sedimentation rate in, 794-795

Arthritis, rheumatoid, erythrocyte sedimentation rate in, 794-795

Ascorbic acid. See *Vitamin C*.

Aspartic acid transminases, in vitamin assay, 376

Aspiration, fine-needle, of thyroid, 699-709
in cancer diagnosis, 728-729
ultrasonographic guidance of, 716-719

Ataxia telangiectasia, lymphocytopenia in, 926

Atherogenesis, free radicals in, 475-480

Atomic absorption spectrometry, in magnesium determination, 213

Atomic absorption spectrophotometry, in zinc determination, 382

Autoimmune neutropenia, 888-889

Autoimmune thyroid disease, 683-697
autoreactive T cells in, 687
defective autoreactivity control in, 683-685
definition of, 685
Graves' disease as, 687-689
Hashimoto's thyroiditis as, 689-690
in congenital hypothyroidism, 649
iodine deficiency and, 692-694
major histocompatibility complex cells in, 690-694
self-tolerance and, 683-685
simple goiter as, 690
thyroid atrophy as, 690
thyroid autoantibodies in, 685-686

Automation, of erythrocyte sedimentation rate, 792-793
of red cell analysis, 775-776
of thyroid function testing, 631-644

Auxochromes, 761-762

Azure B-eosin complex, 767-768

Azure stains, 760-761, 765-767

B lymphocytes, flow cytometry studies of, 836-838
in leukemia, 839-841
in lymphoma, 841-842

Band count, 895-903
alternatives to, 899-900
reference ranges for, 896-897
technical limitations of, 899
uses of, 897-899

"Bare lymphocyte syndrome," 926

Bartter's syndrome, 155

Basal metabolic rate, in elderly persons, 439, 441

Base. See *Acid-base status*.

Basement membrane, of kidney, 3

Bence Jones proteins, in urine, 15-16

Benchmarking, in quality management, 522

Benedict's test, in galactosemia, 425

Bernard-Soulier disease, mean platelet volume in, 945

Bessman classification, anemias, 778-779

Beutler fluorescent spot test, in galactosemia, 425

Bicarbonate, determination of, in hypertension, 288-289
in acid-base balance, 104-105
titration of, in renal tubular acidosis, 124-125

Bioelectrical impedance analysis, in nutritional assessment, 337-338

Biopsy, fine-needle aspiration, of thyroid, 699-709
in cancer diagnosis, 728-729
ultrasonographic guidance of, 716-719
kidney, 30
in kidney failure, 97

Biopterin, determination of, in phenylketonuria, 418

Biotin, in metabolic disease, 427, 429-430

Blood, hypophosphatemia effects on, 202-203

Blood count, instruments for. See *Instrumentation, hematology*.

Blood gas determination, instruments for, 822

Blood pressure, elevated. See *Hypertension*.
lead effects on, 245-248
regulation of, kallikrein-kinin system in, 235-241
leukotrienes in, 241-244
prostaglandins in, 241-245
thromboxanes in, 241-244

Blood smear, review of. See *Peripheral smear review*.

Blood testing. See *Hematologic testing*.

Blood transfusion, hyperphosphatemia in, 187

Blood urea nitrogen, 44
in elderly persons, 269-270

Body composition, in nutritional assessment, 332-340

Body conductivity, total, in nutritional assessment, 337

Body mass index, in elderly persons, 441

Bone, deposition of, hypocalcemia in, 165
hypophosphatemia in, 199
metabolic disease of, in neonates, 394-395

Bone marrow, defects of, neutropenia in, 881-882
suppression of, recovery after, 889-890

Bradykinin, in kidney function, 239-240

Brain, edema of, in hyponatremia, 141-142

Breast milk, nutrition and, 390-392, 394-397, 403-404

Breathing, work of, measurement of, 343

Bricker trade-off hypothesis, in renal failure, 190-191

Brilliant cresyl blue test, in hemoglobinopathies, 810

Broad casts, in urine, 18

Bronchopulmonary dysplasia, treatment of, electrolyte imbalance in, 391

Buffer(s), in acid-base regulation, 104-105

Buffer loading tests, in renal tubular acidosis, 124-126

Buffy coat, erythrocyte sedimentation rate and, 788-789

BUN (blood urea nitrogen), 44 in elderly persons, 269-270

Burns, lymphocytopenia in, 929

Calciferol, in metabolic disease, 428

Calcification, metastatic, in hyperphosphatemia, 190

Calcinosis, tumoral, hyperphosphatemia in, 189

Calciphylaxis, systemic, in hyperphosphatemia, 190

Calcitonin, in hypercalcemia, 176

Calcium, determination of, in hypertension, 290 imbalance of, 157-181. See also *Hypercalcemia; Hypocalcemia*. tests for, 158-160 vs. normal calcium balance, 157-158 in geriatric nutrition, 442-443 in neonatal nutrition, 394-395

Calcium chloride loading test, in renal tubular acidosis, 122

Calcium ethylenediaminetetraacetic acid, in lead toxicity, 247

Calcium gluconate, in hypocalcemia, 167

Calcium oxalate, in urine, 18

Cancer, disseminated intravascular coagulation in, 955 free radicals in, 472-475 hypercalcemia in, 172-173 hyperphosphatemia in, 187-188 lymphocytopenia in, 930 neutrophilia in, 871 thyroid, 725-738 classification of, 726-727 computed tomography of, 721-722 diagnosis of, 727-729 differentiated, thyroglobulin measurements in, 731-732 epidemiology of, 725 magnetic resonance imaging of, 723 prognosis for, 729-730 recurrent, monitoring for, 732-733 treatment of, 729-732 ultrasonography of, 718

Captopril test, in renovascular hypertension, 299

Carbohydrates, hypophosphatemia from, 197-198 in neonatal nutrition, 393-394 thyroid hormone action and, 552-553

Carbon dioxide, in acid-base balance, 104-105 partial pressure of, with phosphate infusion, in renal tubular acidosis, 126 with urinary alkalinization, in renal tubular acidosis, 125-126

Carboxylase deficiency, nutrition support in, 429-430

Cardiopulmonary bypass, lymphocytopenia in, 929

Cardiovascular disease, lymphocytopenia in, 929

Carnitine, deficiency of, in neonates, 393 in metabolic disease, 430

Carotenoids, as antioxidants, 470-471, 474-475

Cartilage-hair syndrome, lymphocytopenia in, 926

Casts, in urine, 17-18 in kidney failure, 93

Catabolic flow phase, in severe illness, 366

Catalase, as free radical scavenger, 469

Catecholamines, excess of, in hypertension, 295-297

Cationic dyes, 761

Cause and effect diagram, in quality management, 522

Cell counters, in hematology. See *Instrumentation, hematology*.

Cell cycle analysis, flow cytometry in, 842, 844

Cell hemoglobin concentration mean, 776, 780

Cellular casts, in urine, 17

Cellular immunodeficiency with immunoglobulins syndrome, 926

Ceruloplasmin, as antioxidant, 470 determination of, 383 in infants, 398

CH50 assay, for complement, 76

CHCM (cell hemoglobin concentration mean), 776, 780

Check sheets, in quality management, 522

Chediak-Higashi syndrome, neutropenia in, 882-884

Chemotherapy, hyperphosphatemia in, 187-188 lymphocytopenia in, 927

Chenzinsky stains, 760-762

4-Chloronaphthol, in myeloperoxidase detection, 913-914

Chlorpropamide, in diabetes insipidus, 147

Cholecalciferol, in neonatal nutrition, 400

Cholesterol, determination of, in hypertension, 290-291

- in wellness testing, 487-489
- in elderly persons, 438
- Christmas disease, 955
- Chromatography, column, in hemoglobin quantitation, 808
 - in prostaglandin determination, 244-245
 - liquid, in ascorbic acid assay, 378-379
 - in free radical measurement, 471-472
 - in retinol assay, 380
 - in tocopherol assay, 380
 - in vitamin B₆ assay, 376
- Chromium, determination of, in nutritional assessment, 384
 - in neonatal nutrition, 398-399
- Chromium-51 ethylenediaminetetraacetic acid, in kidney function assessment, 56
- Chromogens, noncreatinine, 39-41
- Chronic idiopathic neutropenia, 885
- Chronic lymphocytic leukemias, diagnosis of, flow cytometry in, 840-841
- Chronic myeloid leukemia, vs. reactive neutrophilia, 873-874
- Chronic neutrophilic leukemia, vs. reactive neutrophilia, 874
- Chylothorax, lymphocytopenia in, 929
- Circumference, of body parts, in nutritional assessment, 334
- Cirrhosis, Indian childhood, 398
- Clearance, in kidney, 5
 - creatinine. See *Creatinine clearance*.
 - inulin, 34, 36-38, 54-55
 - iodohippurate, 45
 - para-aminohippurate, 34-38, 272
 - radioactive iothalamate, 44-45
- Clinical Laboratory Act of 1988, proficiency testing regulations of, 973-974
- Clinical Laboratory Improvement Amendments of 1988. See under *Regulatory and legislative issues*.
- Clinical pathology, definition of, 516-517
- Clonidine test, in pheochromocytoma, 297
- Clotting function tests, in vitamin K assay, 381
- Coagulation disorders. See *Hemostasis, disorders of*.
- Cobalt, requirements of, in elderly persons, 444-445
- Cofactor-replacement therapy, in metabolic diseases, 427-430
- Colloid nodule, fine-needle aspiration in, 701
- Colony-stimulating factor, in neutropenia, 892
- Colorimetry, in ascorbic acid assay, 378-379
 - in copper determination, 383
 - in zinc determination, 382
- Compartmental analysis, with radioisotopes, in kidney function assessment, 57
- Complement system, activation of, markers for, 77
 - determination of, in glomerular disease, 76-77
 - evaluation of, in nutritional assessment, 461
- Complement-specific immune complex procedure, 73
- Complete blood count, enhancement of, red cell indices in, 781-782
 - in hemoglobinopathies, 809
 - in hypertension, 288
- Computed tomography, in nutritional assessment, 336
 - of thyroid gland, 719-722
- Computers, in quality management, 521
- Concanavalin A, in lymphocyte function testing, 341
- Concentration, urinary, 131-134
 - in elderly persons, 274-275
 - in pediatric patients, 260
- Conductivity, total body, in nutritional assessment, 337
- Conglutinin assay, for immune complexes, 72
- Control charts, in quality management, 523
- Copper, as antioxidant, 470
 - determination of, in nutritional assessment, 382-383
 - in geriatric nutrition, 445
 - in neonatal nutrition, 397-398
- Coronary artery disease, lipoprotein oxidation in, 472-475
- Corticosteroids, lymphocytopenia from, 928-929
- Cortisol, excess of, in hypertension, 294-295
- COUP-TF, thyroid hormone receptor auxiliary proteins and, 534-535
 - transcription factor reactions with, 536
- C1q binding assay, for immune complexes, 71-72
- C-reactive protein, in nutritional assessment, 366
- Creatinine, determination of, 40-41
 - in hypertension, 289-290
 - in nutritional assessment, 335
- Creatinine clearance, 35-44
 - in elderly persons, 270-272
 - in hypertension, 289-290
 - in pediatric patients, 258-259
 - in renal disease, 41-44
 - vs. glomerular filtration rate, 42-43, 55
- O-Cresolphthalein, in calcium determination, 158
- Crithidia kinetoplast staining, in DNA antibody measurement, 74
- Crohn's disease, hypocalcemia in, 164
 - lymphocytopenia in, 928

Crystals, in urine sediment, 18

Cyanocobalamin (vitamin BCC12DD), in geriatric nutrition, 446-447

in metabolic disease, 427-428

in neonatal nutrition, 377, 404

Cycle times, in laboratory testing, 520-521

Cyclic neutropenia, 882-883

Cytchemistry, stains for. See *Stains*.

Cytochrome c oxidase, measurement of, in nutritional assessment, 383

Cytokines, in neutropenia, 892

lymphocytopenia from, 928

Cytology, fine-needle. See *Fine-needle aspiration*.

proficiency testing in, 992

Cytomegalovirus infections, lymphocytosis in, 867

Cytometry. See *Flow cytometry*.

Cytopenia, multilineage, neutropenia in, 885, 888

Cytosolic thyroid hormone binding proteins, 537-538

Data collection tools, in quality management, 522-523

D-Dimer assay, 953

in disseminated intravascular coagulation, 958

Deamino-8-D-arginine vasopressin (DDAVP), in kidney function assessment, 123

Death, predictive models for, 346-347

Dehydration, in neonates, 391

Dehydration test, for kidney concentrating capacity, 133-134

Delayed hypersensitivity, in nutritional assessment, 340-341, 345-346, 461

Dendritic cells, in autoimmune thyroid disease, 690-694

Deoxyuridine suppression test, in folic acid assay, 377

Department of Health and Human Services, laboratory regulations of, 741

Depression, transthyretin levels in, 591

Desmopressin acetate, in diabetes insipidus, 147

Detoxification, in inborn metabolic disease, 430

Diabetes insipidus, 144, 146-147

Diabetes mellitus, nutrition support in, 413

Diabetic ketoacidosis, thyroxine-binding globulin levels in, 589

Dialysis, methods using, in free thyroxine measurement, 613-615, 654-656, 663-667

renal, aluminum bone disease in, hypercalcemia in, 171

hypophosphatemia in, 196

in hyperkalemia, 152

Diese System, for erythrocyte sedimentation rate, 792

Diet, creatinine levels and, 40

for metabolic diseases, 430-432

for nephrolithiasis, 232

for phenylketonuria, 419-422

hyperphosphatemia from, 186-187

hypophosphatemia from, 198-199

renal function and, 37

Dihydrobiopterin, determination of, in phenylketonuria, 418

1 α ,25-Dihydroxyvitamin D assay, 381

Dilution, urinary, 131-134

in elderly persons, 275

inadequate, hyponatremia in, 137-138

Dilutional hyponatremia, 138

Dinitrophenylhydrazine test, in vitamin C assay, 379

Diphenylhydantoin, hypocalcemia from, 165

2,3-Diphosphoglycerate, reduced synthesis of, in hypophosphatemia, 202-203

Diphosphonates, in hypercalcemia, 176

in hyperphosphatemia, 189

Direct immunofluorescence assay, for glomerular basement antibody, 78

Disaccharidase deficiency, nutrition support in, 423

Disseminated intravascular coagulation, 956-959

Diuretics, electrolyte imbalance from, 391

hypercalcemia from, 174

hypophosphatemia from, 195

in hypercalcemia, 176

in nephrolithiasis, 232

Diurnal rhythm, of renal function, 37

DNA, analysis of, in hemoglobinopathies, 811

determination of, flow cytometry in, 842

thyroid hormone receptor interactions with, 533-535

DNA antibody measurement, in glomerular disease, 73-75

Down syndrome, transient myeloproliferative disorder in, 874-875

Drug(s), effects of, on transthyretin levels, 591

thyroxine-binding globulin levels, 589

hypocalcemia from, 166

interactions with nutrients, 325

kidney injury from, in pediatric patients, 263-264

lupus anticoagulant from, 962

lymphocytosis from, 867

neutropenia from, 882, 884-885

neutrophilia from, 871

Dual photon absorptiometry, in nutritional assessment, 336

Dyes. See *Stains*.

Dysfibrinogenemia, in liver disease, 959

Ebb phase, in severe illness, 366

Edema, brain, in hyponatremia, 141–142 from infant formulas, 393

Education, for quality management, 518–519

Effective renal plasma flow, 6 calculation of, 35 measurement of, in elderly persons, 272–274

radioisotopes in, 61–64

Ektadem slide method, in calcium determination, 158

Elderly persons, kidney function in, assessment of, 269–277 nutrition in, 435–455 assessment of, 325, 348, 436–438 energy requirements, 438–441 mineral requirements in, 442–445 physiology changes and, 435–436 protein requirements, 441–442 psychological changes and, 436 socioeconomic changes and, 436 vitamins in, 445–451

Electrolyte balance, in neonates, 390–391

Electron spin resonance, in free radical measurement, 471

Electrophoresis, hemoglobin, 803–808 acid, 804 alkaline, 803–804 globin chain, 804 isoelectric focusing, 804, 806 quantitative, 806, 808 protein, in immune complex measurement, 70

ELISA. See *Enzyme-linked immunosorbent assay*.

Endothelium-derived relaxing factor, 467

Enema, phosphorus-containing, hyperphosphatemia in, 185–186

Energy requirements, for elderly persons, 438–441

Enteral nutrition, 500

Enzyme(s), renal, in urine, 15

Enzyme immunoassay, for prostatic acid phosphatase, 282

Enzyme-linked immunoassay, for immune complexes, 73

Enzyme-linked immunosorbent assay, for DNA antibodies, 74–75 for kallikrein-kinin system activity, 240–241

Eosin stains, 761–765, 767–768

Eosinophils, in urine, 16–17

Epilepsy, thyrotropin measurements in, 678–679

Epinephrine, excess of, in hypertension, 295–297

hypophosphatemia from, 198

Epstein-Barr virus infection, lymphocytosis in, 864–866

Ergocalciferol, in neonatal nutrition, 400

Erythrocyte(s), abnormal, in hypophosphatemia, 202–203

flow cytometry studies of, 847 in urine sediment, 16 morphology of, in hemoglobinopathies, 809

Erythrocyte enzyme activity tests, in vitamin assay, 376

Erythrocyte fragility test, in vitamin E assay, 380–381

Erythrocyte glutathione reductase test, in vitamin assay, 375

Erythrocyte indices. See *Red cell indices*.

Erythrocyte sedimentation rate, 787–800 automation of, 792–793 background of, 788–791 buffy coat formation and, 788–789 closed systems for, 792–793 disposable tubes for, 791–792 methodology for, 791–793 performance characteristics of, 792 quality control programs for, 793 reference range for, 788 usefulness of, 794–796

Erythrocyte superoxide dismutase, measurement of, in nutritional assessment, 383

Erythrocyte transketolase stimulation test, in vitamin assay, 375

Erythroid disorders, diagnosis of, flow cytometry studies in, 847

Erythropoietin, synthesis of, in kidney, 10

Erythro-5,6,7,8-tetrahydrobiopterin loading test, in phenylketonuria, 418

Essential fatty acids, deficiency of, in neonates, 392–393

Estrogens, hypophosphatemia from, 198 therapy with, thyroxine-binding globulin levels in, 588

Ethane hydroxydiphosphonate, in hypercalcemia, 176

Euvolemic hyponatremia, 144

Euvolemic hyponatremia, 137–138, 142

Exercise, mean platelet volume in, 944

External imaging methods, in kidney function assessment, 60–61, 63–64

Factor VIII, antibodies to, 961–962

Factor VIII (*Continued*)
 deficiency of, 954-955

Factor XII deficiency, 964

Failure to thrive, in neonates, 391

Familial dysalbuminemic
 hyperthyroxinemia, 591-592

Familial hyperkalemic periodic paralysis, 152

Familial hypocalciuric hypercalcemia, 171

Familial hypophosphatemic rickets, 400-401

Fanconi syndrome, hypophosphatemia in, 194

Fanconi's anemia, neutropenia in, 882-883

Farr radioimmunoassay, for DNA antibodies, 74

Fat(s), in neonatal nutrition, 392-393
 malabsorption of, hypocalcemia in, 164
 in neonates, 393

metabolic disorders of, nutrition support in, 416

Fatty acids, essential, deficiency of, in neonates, 392-393

Fechtner syndrome, mean platelet volume in, 945

Felty's syndrome, lymphocytopenia in, 930

Ferritin, determination of, in wellness testing, 486-487

Fetal hemoglobin, detection of, 809-811
 acid elution for, 910-912
 persistence of, 803
 quantitation of, 808

Fetal-maternal hemorrhage, detection of, flow cytometry in, 847

Fever, band count in, 898

Fibronectin, in nutritional assessment, 339-340, 364-365

Filtration fraction, 6
 calculation of, 36

Financial implications, of malnutrition, 493-509

Fine-needle aspiration, of thyroid, 699-709
 in cancer diagnosis, 728-729
 ultrasonographic guidance of, 716-719

Flagging systems, for hematology instruments, 824-825

Flow charts, in quality management, 522

Flow cytometry, 831-852
 advantages of, 835-836
 applications of, 835
 data presentation in, 835
 in cell cycle analysis, 842, 844
 in DNA content determination, 842, 844
 in erythrocyte studies, 847
 in granulocyte assay, 845-846
 in human immunodeficiency virus infection monitoring, 844-845
 in immunologic monitoring, 844-845

in lymphoproliferative disorder diagnosis, 838-842

acute lymphocytic leukemia, 838-840

acute mixed lineage leukemias, 840

chronic lymphocytic leukemias, 840-841

lymphoma, 841-842

in monocyte assay, 845-846

in multiple myeloma diagnosis, 842

in plasma cell dyscrasias diagnosis, 842

in platelet studies, 846

instrument components for, 832

monoclonal antibodies in, 836-838

overview of, 831-836

quality control in, 847-848

stains for, 832-833

Fludrocortisone, in hyperkalemia, 152

Fluid balance, in neonates, 390-391

Fluid intake, in nephrolithiasis, 232

Fluorescent dyes, for flow cytometry, 832-833

in magnesium determination, 216-217

Fluoride requirements, in elderly persons, 445

Folic acid, assay for, 376-377
 in geriatric nutrition, 446-447
 in neonatal nutrition, 404

Folin-Wu reaction, in creatinine determination, 40-41

Follicular thyroid carcinoma, 726, 730

Follicular thyroid neoplasia, fine-needle aspiration in, 701-702

Food and Drug Administration, laboratory regulations of, 741

Fractional excretion of filtered sodium test, in kidney failure, 94-97

Free radicals, antioxidants for, 468
 cancer and, 474-475
 in atherogenesis, 478-480
 transition metals as, 469-470
 vitamins as, 470-471

definition of, 465-466

enzymes for scavenging of, 468-469

in atherogenesis, 475-480

in carcinogenesis, 472-475

measurement of, 471-472

sources of, 465-467

Free thyroxine. See under *Thyroxine*.

Fructose, hypophosphatemia from, 198

Fructose intolerance, nutrition support in, 423

Furosemide, in hyperkalemia, 152

Furosemide test, in renal tubular acidosis, 124

Galactitol, determination of, 425

Galactose, in fruits and vegetables, 426

Galactosemia, nutrition support in, 422-427
pathophysiology of, 412, 417

Gamma camera, in glomerular filtration rate determination, 60-61, 63-64

Gates method, for glomerular filtration rate determination, 60

Gene expression, thyroid hormone receptors in, 535-536

Gene transcription, thyroid hormone receptors in, 536

Giems stains, 765-766, 906-907

Globin chain electrophoresis, hemoglobin, 804

Globin chain synthesis ratios, in hemoglobinopathies, 810

Glomerular basement antibody disease, serologic evaluation in, 78-79

Glomerular disease, serologic evaluation of, 69-87

- antineutrophil cytoplasmic antibodies in, 79-81
- complement determination in, 76-77
- DNA antibody measurements in, 73-75
- glomerular basement antibody disease, 78-79
- immune complex measurements in, 70-73
- membranoproliferative glomerulonephritis, 77
- postinfectious glomerulonephritis, 81-82

Glomerular filtration rate, clearance and, 5
decreased, hyperphosphatemia in, 184-186

estimation of, clearance in, 34-38, 53-55
creatinine measurements in, 39-44
in elderly persons, 269-272
in pediatric patients, 257-259
radioisotopes in, 44-45, 55-61
renal plasma flow in, 33-36
urea measurement in, 44

in kidney failure, 97-98

lead effects on, 245-246

normal, 37

regulation of, 3-5
variations in, 37-38

vs. creatinine clearance, 42-43
vs. plasma creatinine, 42-43

Glomerulitis, with vasculitis, diagnosis of, 92

Glomerulonephritis, crescentic, serologic evaluation of, 78-79
in hepatitis B, 82
membranoproliferative, serologic evaluation in, 77
postinfectious, serologic evaluation in, 81-82

Glomerulus, anatomy of, 3

permeability of, in elderly persons, 276

Glucagon, hypophosphatemia from, 198

Glucagon provocation test, in pheochromocytoma, 297

Glucose, determination of, in hypertension, 290

hypophosphatemia from, 201-202
in hyperkalemia, 152
tubular reabsorption of, 47-48

Glutathione peroxidase, as free radical scavenger, 469

measurement of, in selenium deficiency, 398

Glycogen storage disease, nutrition support in, 413, 431

Goiter, in thyroid hormone resistance, 566-567

intrathoracic, computed tomography of, 720
magnetic resonance imaging of, 723
simple, 690

Goodpasture's syndrome, serologic evaluation in, 78-79

Granular casts, in urine, 17-18

Granulocyte(s), assay of, flow cytometry in, 845-846
defects of, neutropenia in, 881-882

Granulocyte colony-stimulating factor, in neutropenia, 892

Granulocytopenia, 870

Granulomatosis, hypercalcemia in, 173-174
Wegener's, antineutrophil cytoplasmic antibodies in, 79-81

Graves' disease, autoantibodies in, 687-689
ophthalmopathy in, computed tomography of, 721
ultrasonography of, 718

Grünwald stains, 764-765

Hairy cell leukemia, diagnosis of, flow cytometry in, 841
stains for, 918-919

Harvey hospital prognostic index, in nutritional assessment, 346

Hashimoto's thyroiditis, autoantibodies in, 689-690
fine-needle aspiration in, 701

Health Care Financing Administration, laboratory regulations of, 740-741, 985-986

Heinz body preparation, 912-913

Hematocrit, instruments for, 822
Zeta, 792

Hematologic testing, 759-994
band count, 895-903
cell counting, 817-829
cytochemistry, 905-921
erythrocyte sedimentation rate, 782-800

Hematologic testing (Continued)

- flow cytometry in, 831-852
- in hemoglobinopathies, 801-816
- in hemostasis, 951-971
- in lymphocytopenia, 923-934
- in neutropenia, 879-893
- in reactive lymphocytosis, 863-870
- in reactive neutrophilia, 850-875
- instrumentation for, 817-829
- mean platelet volume, 937-950
- peripheral smear in, 853-861
- proficiency testing in, 973-985
- red cell indices, 773-785
- stains in, 759-771

Hematopoietic system, flow cytometry

- studies of, 836-838

Hematuria, 16

Hemochromatosis, perinatal, 396

Hemodialysis, in hyperkalemia, 152

Hemoglobin, composition of, 802-803

- fetal, detection of, 809-811
- acid elution for, 910-912
- persistence of, 803
- quantitation of, 808
- solubility tests for, in hemoglobinopathies, 809
- unstable, detection of, 809
- variant forms of, 802-803

Hemoglobin distribution width, 776

Hemoglobin S, detection of, 803-804, 806, 808-809, 811

Hemoglobinopathies, diagnosis of, 801-816

- brilliant cresyl blue test for inclusion bodies, 810
- complete blood count in, 809
- DNA analysis in, 811
- electrophoresis in, 803-808
- globin chain synthesis ratios in, 810
- hemoglobin composition and, 802-803
- hemoglobin quantitation in, 806, 808
- hemoglobin solubility tests in, 809
- Kleihauer-Betke stain for, 810
- methods for, 803
- monoclonal antibody tests in, 809
- recommendations for community hospital laboratory, 811-813
- red cell morphology in, 809
- reference laboratory tests in, 810-811
- unstable hemoglobin screen in, 809

Hemolytic anemia, diagnosis of, staining for, 912-913

- from infant formulas, 393

Hemophilia, lymphocytopenia in, 930

Hemophilia A, 954-955

Hemophilia B, 955

Hemorrhage, fetal-maternal, detection of, flow cytometry in, 847

in disseminated intravascular coagulation, 956-959

in liver disease, 960-961

Hemostasis, 951-971

- disorders of, acquired circulating anticoagulants, 961-963
- congenital coagulation defects, 954-956
- disseminated intravascular coagulation, 956-959
- hypercoagulability, 964-967
- in liver disease, 959-961
- elements of, 952-954

Henderson equation, 106-107

Henderson-Hasselbalch equation, 105

Hepatitis, retinol-binding protein levels in, 362

Hepatitis B, glomerulonephritis in, 82

Heterophil antibody test, in infectious mononucleosis, 865-866

High-dose hook effect, in thyrotropin assay, 676-677

Hip circumference, in nutritional assessment, 334

Histograms, in quality management, 522

HIV infection. See *Human immunodeficiency virus infection*.

Hodgkin's disease, erythrocyte sedimentation rate in, 795

- hypercalcemia in, 172
- lymphocytopenia in, 929

Hormones, thyroid. See *Thyroid hormone(s)*.

Hospital, length of stay, predictive models for, 346-348

Hospital prognostic index, in nutritional assessment, 346

Human herpes virus-6 infection, lymphocytosis in, 867

Human immunodeficiency virus infection, acute, lymphocytosis in, 867

- flow cytometry studies in, 844-845
- hypocalcemia in, 166
- lymphocytopenia in, 926
- mean platelet volume in, 944
- thyroxine-binding globulin levels in, 589

Human milk, nutrition and, 390-392, 394-397, 403-404

Hungry bone syndrome, hypocalcemia in, 165

- hypophosphatemia in, 199

Hürthle cell cancer, 726

Hürthle cell neoplasms, fine-needle aspiration in, 702

Hyaline casts, in urine, 17

Hydrogen ion, conversion to pH, 107-108

- excretion of, in elderly persons, 275

Hydrogen peroxide, formation of, from free radical reactions, 466

Hydroxyl radical, as oxidant, 466-467

11-Hydroxylase deficiency, hypertension in, 299-300

17 α -Hydroxylase deficiency, hypertension in, 299-300

25-Hydroxyvitamin D assay, 381

Hyperalbuminemia, hypercalcemia in, 168

Hypercalcemia, **168-177**
causes of, 168
differential diagnosis of, 168-175
familial hypocalciuric, 171
humoral, 172-173
hypophosphatemia with, 193
iatrogenic, 174
malignancy-associated, 172-173
of infancy, 174-175

Hypercalciuria, absorptive, in kidney stone formation, 230

Hyperchloremic metabolic acidosis, 109-110, 112-113

Hypercholesterolemia, wellness testing for, 487-489

Hypercoagulability states, 964-967

Hyperkalemia, **149-153**
causes of, 149-152
familial periodic paralysis in, 152
in hypokalemia therapy, 155
pseudo-, 149
treatment of, 152-153

Hyperlipidemia, pseudohyponatremia in, 137

Hypernatremia, **142-147**
assessment of, 146
etiology of, 142, 144
euvolemic, 144
hypervolemic, 144
hypovolemic, 144
in neonates, 391
symptoms of, 144, 146
treatment of, 146-147

Hyperparathyroidism, hypercalcemia in, 168-172
hypocalcemia in, 163-166
hypophosphatemia in, 193-195
primary, 168-170
secondary, 170
tertiary, 170-171

Hyperphenylalaninemia. See *Phenylketonuria*.

Hyperphosphatemia, **184-192**
consequences of, 189-191
differential diagnosis of, 184-189
hypocalcemia in, 165-166
in infants, 188
treatment of, 191-192

Hyperproteinemia, pseudohyponatremia in, 137

Hypersensitivity, delayed, in nutritional assessment, 340-341, 345-346, 461

Hypersplenism, neutropenia in, 884, 888

Hypertension, **287-302**
blood tests in, 288-291

in adrenal disorders, 292-297

in renal disorders, 297-299

kallikrein-kinin system in, 240

lead burden and, 245-247

prostaglandins in, 243-244

renovascular, 297-299

unusual causes of, 299-300

urine tests in, 291

Hyperthermia, therapeutic, hypophosphatemia in, 195-196

Hyperthyroidism, free thyroxine levels in, 658-660

hypercalcemia in, 173

thyrotropin measurements in, 679-681

thyroxine-binding globulin levels in, 588

Hyperventilation, hypophosphatemia in, 196-197

Hypervolemic hypernatremia, 144

Hypervolemic hyponatremia, 138

Hypoalbuminemia, 339, 356-357, 591-592
hypocalcemia in, 161

Hypocalcemia, **160-168**
causes of, 160
clinical features of, 166-167
differential diagnosis of, 161-166
hyperphosphatemia and, 188, 190
neonatal, 166
treatment of, 167-168

Hypocalciuric hypercalcemia, familial, 171

Hypocomplementemia, in glomerular disease, 76-77

Hypofibrinogenemia, in disseminated intravascular coagulation, 955

Hypoglycemia, nutrition support in, 413

Hypokalemia, **153-155**
causes of, 153-154
in hypertension, 293-294
treatment of, 154-155

Hypomagnesemia, hypocalcemia in, 162-163

hypophosphatemia with, 196

Hyponatremia, **136-142**
acute, 138-139
after prostatectomy, 139
assessment of, 140
clinical presentation of, 136-137
dilutional, 138
euvolemic, 137-138, 142
hypervolemic, 138
hypovolemic, 137-138, 142
in neonates, 391
in oxytocin therapy, 139
in preterm infants, 261
pathophysiology of, 137-139
postoperative, 139
progressive, 138
pseudo-, 137
symptoms of, 139-140
treatment of, 140-142

Hypoparathyroidism, hyperphosphatemia in, 188
 hypocalcemia in, 161–163

Hypophosphatemia, 192–204
 acute, 203
 congenital X-linked, 194
 consequences of, 200–203
 differential diagnosis of, 192–199
 fructose-induced, 198
 hypercalcemia with, 193
 phosphate therapy for, hyperphosphatemia in, 187
 profound, 200–201
 redistribution, 196–199
 renal, 194–196
 rickets in, 400–401
 treatment of, 203–204

Hypothyroidism, congenital, 645–652
 biochemical features of, 650
 clinical features of, 649
 epidemiology of, 648
 etiology of, 648–649
 prognosis for, 650–651
 screening methodology for, 646–648
 treatment of, 650
 free thyroxine levels in, 658–660
 mean platelet volume in, 946
 thyrotropin measurements in, 679–681
 thyroxine-binding globulin levels in, 588

Hypotransferrinemia, 358

Hypovolemic hypernatremia, 144

Hypovolemic hyponatremia, 137–138, 142

Idiogenic osmoles, 141–142

Imaging, in kidney failure, 97, 99
 of thyroid gland. See under *Thyroid gland*.

Immobilization, hypercalcemia in, 174

Immune complexes, anti-DNA antibodies in, 73–75
 complement activation by, 76–77
 in glomerulonephritis, 77, 81–82
 measurement of, in glomerular disease, 70–73

Immune function, flow cytometry studies of, 836–838
 nutrition and, 457–463
 assessment in, 340–341, 460–462
 in nutritional deficiency, 458–460

Immunoassay, for free thyroxine, Sephadex absorption method for, 624–625
 single-step approach to, 617–624
 analogue protein binding in, 620–622
 labeled analogue methods in, 618–620
 labeled antibody methods for, 622–624
 two-step direct approach to, 615–617
 for thyroid function testing, automation of, 631–644
 competitive, 633
 data management for, 633–634
 disadvantages of, 635
 heterogenous, 632–633
 homogenous, 632–633
 immunometric, 633
 performance of, 638–643
 reagent stability in, 633
 sample management in, 634
 signal detection in, 634–635
 systems for, 635–638

Immunoblasts, in reactive lymphocytosis, 869

Immunocytochemical stains, 919

Immunodeficiency, flow cytometry studies in, 844–845
 lymphocytopenia in, 925–926

Immunoglobulin(s), light chains of, in urine, 15–16

Immunoglobulin G, thyrotropin-binding, 687

Immunohistochemistry, of prostatic acid phosphatase, 284

Immunologic evaluation, flow cytometry in, 844–845
 Immunoradiometric assay, for thyroxine-binding globulin, 594

Indian childhood cirrhosis, 398

Indirect immunofluorescence assay, for antineutrophil cytoplasmic antibodies, 79–81
 for glomerular basement antibody, 78

Infants, newborn. See *Neonates*.

Infections, erythrocyte sedimentation rate in, 795–796
 neutropenia in, 884–885
 neutrophilia in, 870–871
 reactive lymphocytosis in, 864

Infectious mononucleosis, 864–866
 diagnosis of, 864–866
 lymphocyte morphology in, 864
 symptoms of, 864

Inflammation, transthyretin levels in, 591

Inflammatory bowel disease, lymphocytopenia in, 928

Influenza, lymphocytopenia in, 930

Infrared interactance, in nutritional assessment, 336

Infrared spectroscopy, in kidney stone analysis, 230

Instrumentation, hematology, 817–829
 for centralized laboratories, 820–821
 for intensive care units, 822
 for outpatient clinics, 822–823

for reticulocyte counting, 823-824
for satellite laboratories, 821-824
performance of, 819-820
regulatory concerns in, 818-819
selection of, 824-828

Insulin, hypophosphatemia from, 198
in hyperkalemia, 152

Insulin growth factor 1 (somatomedin C),
in nutritional assessment, 362-364

Interleukins, in neutropenia, 892
in nutritional assessment, 366-367

Interstate Quarantine Regulations, for
specimen shipping, 742

Inulin clearance, 5, 34, 36-38, 54-55

Iodine, deficiency of, major
histocompatibility complex antigens
and, 692-694
requirements of, in elderly persons, 444

Iodine radioisotopes, in thyroid imaging,
711, 713-714

Iododiatrizoate, labeled, in kidney function
assessment, 55

Iodohippurate, labeled, in kidney function
assessment, 45

Ion-selective electrodes, in calcium
determination, 159

Iothalamate, labeled, in kidney function
assessment, 44-45, 55-56

Iron, as oxidant, 469
in geriatric nutrition, 443-444
in neonatal nutrition, 395-396
stains for, 908-910
transferrin binding to, 357-358

Iron deficiency anemia, 443-444
red cell indices in, 777-781
wellness testing for, 486-487

Islet cell tumors, hypercalcemia in, 173

Isoelectric focusing electrophoresis,
hemoglobin, 804, 806

Isopropanol precipitation test, in
hemoglobinopathies, 809

Isotope studies, in nutritional assessment,
335

Jaffe reaction, in creatinine determination,
40-41

Jenner stains, 764-765

Joint Commission for Accreditation of
Healthcare Organizations,
requirements of, 740

Kallikrein-kinin system, in kidney function,
9, 235-241

Kappa:lambda test, in lymphoma, 841

Kayexalate, in hyperkalemia, 152

Ketoacidosis, diabetic, thyroxine-binding
globulin levels in, 589

Kety-Renkin-Crone equation, 604-605

Kidney, anatomy of, 1-8
biopsy of, 30, 97
blood flow of, 6
in elderly persons, 273-274
blood supply of, 2-4
enzymes of, in urine, 15
failure of. *See Kidney failure.*
function of. *See Kidney function.*
injury of, in pediatric patients, 262-264
parenchymal disease of, hypertension in,
299

stones in. *See Nephrolithiasis.*

transplantation of, hypophosphatemia
after, 194

tubules of, anatomy of, 6-8
function of, 6-8
assessment of, 46-48, 259-260, 274-
275

necrosis of, 91-92

phosphate reabsorption in, 188-189,
194-195

potassium secretion in, 150

urine acidification in. *See Renal tubular*

acidosis.

vascular disease of, hypertension in, 297-
299

Kidney failure, chronic, creatinine in, 41-42

diagnosis of, 89-102
acute, 89-97
biopsy in, 97
chronic, 97-100
imaging in, 97, 99
laboratory procedures in, 93-97, 99

parenchymal, 91-92

physical examination in, 92-93

postrenal, 91

prerenal, 89-91

hypercalcemia in, 177

hyperkalemia in, 149-150

hyperphosphatemia in, 184-186, 190-191

hypocalcemia in, 163

mean platelet volume in, 944-945

recovery from, hypercalcemia in, 171

retinol-binding protein levels in, 361

thyroxine-binding globulin levels in, 588

Kidney function. *See also Glomerular*

filtration rate; Urine.

assessment of, antineutrophil cyto-
plasmic antibodies in, 79-81

blood urea nitrogen in, 44, 269-270

complement determination in, 76-77

concentrating ability, 131-134

diluting ability, 131-134

DNA antibody measurements in, 73-
75

glomerular, 33-46

Kidney function (Continued)
 immune complex measurements in, 70-73
 in elderly persons, 269-277
 in glomerular basement antibody disease, 78-79
 in membranoproliferative glomerulonephritis, 77
 in pediatric patients, 257-267
 in postinfectious glomerulonephritis, 81-82
 in renal tubular acidosis, 117-129
 radioisotope methods in, 44-45, 53-68
 serologic methods in, 69-87
 tubular, 46-48, 259-260, 274-275
 urinalysis in. See *Urinalysis*.
 urinary sediment analysis in, 16-18, 93-94
 clearance in. See *Clearance*.
 electrolyte imbalance and, calcium, 157-181
 magnesium, 209-223
 phosphate, 183-207
 potassium, 149-156
 sodium, 135-148
 hypercalcemia effects on, 175-176
 hypertension and, 297-299
 in acid-base regulation, 105, 108
 in diabetes insipidus, 144
 in hypertension, 291
 in potassium balance, 149, 261-262
 kallikrein-kinin system in, 9, 235-241
 lead effects on, 245-248
 leukotrienes in, 241-244
 prostaglandins in, 241-245
 regulation of, 8-10
 thromboxanes in, 241-244
 tubular, 6, 8
 assessment of, 46-48
 function of, 259-260
 variations in, 37-38
 Kinin(s), in kidney function, 239-240
 receptors for, 240
 Kininases, in kidney function, 237
 Kininogens, in kidney function, 237
 Kleihauer-Betke stain, in
 hemoglobinopathies, 810
 Kostmann's syndrome, neutropenia in, 882-883
 Kwashiorkor, albumin levels in, 357
 immunodeficiency in, 459

Laboratory management, quality in, 513-514, 515-524
 Lactic acidosis, 110
Lactobacillus casei, in folic acid assay, 377

Lactobacillus leishmanii, in vitamin B₁₂ assay, 377
 Lactose, in neonatal nutrition, 393-394
 Lactose tolerance test, 394
 Lasers, in flow cytometry, 832-833
 in red cell analysis, 775-776
 Laxatives, phosphorus-containing, hyperphosphatemia in, 186
 Lead, determination of, 248
 kidney function and, 245-248
 Leishman stains, 765
 Length of stay in hospital, nutritional factors in, 495, 499, 503-506
 predictive models for, 346-348
 Leukemias, diagnosis of, cytochemistry in, 913
 flow cytometry in, 838-841
 hairy cell, stains for, 918-919
 stains for, 913-914, 917-919
 vs. lymphocytosis, 869-870
 vs. reactive neutrophilia, 873-874
 Leukocyte(s), aplasia of, neutropenia in, 884
 in urine sediment, 16-17
 Leukocyte alkaline phosphatase score, 916-917
 Leukocyte ascorbic acid assay, 378-379
 Leukocyte count, instruments for, 819-820
 Leukocyte esterase stains, 917-918
 Leukocyte terminal deoxynucleotidyl transferase, determination of, in nutritional assessment, 461
 Leukotrienes, in kidney function, 241-244
 Lillie stains, 766
 Linoleic acid deficiency, in neonates, 392-393
 Lipid(s), in neonatal nutrition, 392-393
 metabolic disorders of, nutrition support in, 416
 Lipid peroxides, formation of, in free radical reactions, 467
 Lipogenesis, thyroid hormones in, 553-554
 Lipolysis, thyroid hormones in, 553-554
 Lipoproteins, low-density, oxidation of, in atherogenesis, 475-480
 Literature, on quality management, 523-524
 Lithium therapy, hypercalcemia in, 171
 Lithotripsy, in nephrolithiasis, 232-233
 Liver disease, coagulation disorders in, 957-959
 hypocalcemia in, 165
 thyroxine-binding globulin levels in, 588
 Lofenac formula, in phenylketonuria, 419-422
 Low-density lipoproteins, oxidation of, in atherogenesis, 475-480
 Lupus anticoagulant, 962-964
 Lycopene, as antioxidant, 471

Lymphangiectasia, lymphocytopenia in, 929

Lymphoblasts, studies of, flow cytometry in, 838-839

Lymphocyte(s). See also *B lymphocytes; T lymphocytes*.
in urine, 17
total count of, in nutritional assessment, 341, 460-461

Lymphocyte count, 923-924
in reactive lymphocytosis, 863-864
instruments for, 820

Lymphocytopenia, 923-934
cell counting in, 923-924
lymphoid system kinetics in, 924-925
pathogenesis of, decreased production in, 925-926
increased destruction in, 926-927
multifactorial causes in, 929-930
redistribution in, 927-929

Lymphocytosis, malignant, vs. benign, 869-870
reactive, 863-870
causes of, 864
immunoblasts in, 869
in cytomegalovirus infections, 867
in HIV infection, 867
in human herpes virus-6 infection, 867
in infectious mononucleosis, 864-866
in toxoplasmosis, 867
in viral infections, 867
lymphocyte counts in, 863-864
mature, 867-869
transient, 868-869
vs. malignant lymphocytosis, 869-870

Lymphoma, fine-needle aspiration in, 702
hypercalcemia in, 172-173
lymphoblastic, diagnosis of, flow cytometry in, 839
malignant, diagnosis of, flow cytometry in, 841-842

Lymphoproliferative disorders, diagnosis of, flow cytometry in, 838-842

Lysine vasopressin, in diabetes insipidus, 147

Macrocytic anemia, red cell indices in, 781

Macrothrombocytopenia, mean platelet volume in, 943

Magnesium, 209-223
absorption of, measurement of, 214
deficiency of (hypomagnesemia), 162-163, 196
determination of, 213-219
distribution of, 211
excretion of, measurement of, 214-215
in cardiovascular function, 209-210

intracellular, determination of, 216-219
regulation of, 211-213

Magnetic resonance imaging, in nutritional assessment, 336
of thyroid, 722-723

Major histocompatibility complex antigens, in autoimmune thyroid disease, 690-694

Malabsorption, correction of,
hypercalcemia in, 170
hypophosphatemia in, 193
of carbohydrates, nutrition support in, 423
of fat, in neonates, 393

Malachowski stains, 762-763

Malignancy. See *Cancer*.

Malnutrition, assessment of. See *Nutritional assessment*.
biochemical, 316
catabolic flow phase of, 366
clinical features of, 317
consequences of, 494
development of, 316-317
ebb phase of, 366
immune function in, 340-341, 457-463
in elderly persons, 348
in severe illness, 366
incidence of, 493
lymphocytopenia in, 926
nutrition support in, costs of, 500-501
criteria for, 494-495
multidisciplinary team for, 501
routes for, 499-500
protein levels in. See *Nutritional assessment, proteins in*.
symptomatic, 317
thyroxine-binding globulin levels in, 589
transthyretin levels in, 591

Manganese, determination of, in nutritional assessment, 384
in geriatric nutrition, 444-445
in neonatal nutrition, 398-399

Maple syrup urine disease, nutrition support in, 413

Maximum tubular transport capacity, 274

May stains, 764-765

May-Hegglin anomaly, mean platelet volume in, 943

MCH (mean cell hemoglobin), 773

MCHC (mean cell hemoglobin concentration), 773-774

MCV (mean cell volume), 773-774, 776-778

Mean cell hemoglobin, 773

Mean cell hemoglobin concentration, 773-774

Mean cell volume, 773-774, 776-778

Mean platelet volume, 937-950
biological significance of, 937-941
clinical utility of, 943-947

Mean platelet volume (*Continued*)
 methodologic problems with, 941-943

Measles, lymphocytopenia in, 930

Mechanical ventilation, muscular weakness
 in, nutrition support in, 342-343

Medicare, regulatory aspects of, 739-740

Medullary thyroid carcinoma, 726-727
 fine-needle aspiration in, 703
 prognosis for, 730
 treatment of, 730

Megaloblastic anemia, in folic acid
 deficiency, 376-377
 neutropenia in, 888

Membranoproliferative glomerulonephritis,
 serologic evaluation in, 77

Menaquinone assay, 381

Menkes' steely hair syndrome, copper
 deficiency in, 397-398

Metabolic acidosis. See under *Acidosis*.

Metabolic alkalosis, diagnosis of, 113
 in mixed acid-base disorders, 114

Metabolic disorders, inborn, 409-434
 categories of, 411
 cofactor-replacement therapy in, 427-430
 detoxification therapy in, 430
 dietary formulations for, 430-432
 nutrient prohibition in, 422-427
 nutrient restriction in, 412-422
 prenatal screening for, 411-412
 screening for, 411-412
 of bone, in neonates, 394-395

Metals. See also specific metal.
 trace, in nutritional assessment, 382-384

Metanephrine, determination of, 295-296

Metastatic carcinoma, thyroid, fine-needle
 aspiration in, 703

Methyl violet stain, 912-913

Methylene blue stains, 760-768, 906-908

Methylene violet stains, 763-764

3-Methylhistidine, determination of, in
 nutritional assessment, 335

Microcytic anemia, differential diagnosis
 of, red cell indices in, 777-781
 mean platelet volume in, 944-945

Milk, galactosemia and, 422-427
 human, nutrition and, 390-392, 394-397,
 403-404

Milk-alkali syndrome, 174

Minerals. See also specific mineral.
 as antioxidants, 469
 as oxidants, 469
 in geriatric nutrition, 442-445
 in neonatal nutrition, 394-399

Minimal residual disease, detection of, flow
 cytometry in, 840-841

Mithramycin, in hypercalcemia, 176

Molybdenum, determination of, in
 nutritional assessment, 384

 in geriatric nutrition, 444-445
 in neonatal nutrition, 398-399

Monoclonal antibodies, in flow cytometry,
 836-838

Monoclonal antibody tests, in
 hemoglobinopathies, 809

Monoclonal gammopathy of undetermined
 significance, diagnosis of, flow
 cytometry in, 842

Monocyte(s), assay of, flow cytometry in,
 845-846

Monocyte count, instruments for, 820

Mononucleosis, infectious, 864-866

Monosaccharide malabsorption, nutrition
 support in, 423

MSUD diet, in metabolic disease, 420-421,
 431

Mullen prognostic nutritional index, 320,
 345

Multidrug resistant gene, flow cytometry
 studies of, 840

Multiple endocrine neoplasia,
 hypercalcemia in, 170

Multiple myeloma, diagnosis of, flow
 cytometry in, 842
 hypercalcemia in, 172

Muscle function, evaluation of, in
 nutritional assessment, 341-343

Myasthenia gravis, lymphocytopenia in,
 930

Myeloblasts, detection of, stains for, 913-914

Myeloid cells, flow cytometry studies of,
 836-838

Myelokathexis, neutropenia in, 882

Myeloma, multiple, diagnosis of, flow
 cytometry in, 842
 hypercalcemia in, 172

Myeloperoxidase, detection of, stains for,
 913-914

Myeloproliferative disorders, vs. reactive
 neutrophilia, 873-874

Myocardial infarction, mean platelet
 volume in, 947

Myopathy, in hypophosphatemia, 201

Necrosis, acute tubular, diagnosis of, 91-92

Neonates, hypothyroidism in, 645-652
 neutropenia in, 888

 nutrition in, carbohydrates, 393-394
 electrolytes, 390-391
 fluids, 390-391
 lipids, 392-393
 minerals, 394-399
 protein, 391-392
 vitamins, 399-404

 sepsis in, band count in, 898

Neoplasms. See also *Cancer*.
 transthyretin levels in, 591

Neopterin, determination of, in phenylketonuria, 418

Nephritic factor of the terminal pathway, in glomerulonephritis, 77

Nephritis, acute interstitial, diagnosis of, 92

Nephrolithiasis, 225-234
 causes of, 226, 230
 history in, 227-228
 laboratory investigation of, 228-232
 metabolic evaluation of, 226-227
 natural history of, 225-226
 physical examination in, 228
 stone types in, 228
 treatment of, 232-233

Nephrolithotomy, percutaneous, 232

Nephron, anatomy of, 3, 7

Nephrotic syndrome, 27-30

Net acid excretion test, in renal tubular acidosis, 120

Net charge, urinary, in renal tubular acidosis, 120-121

Neurologic disorders, in hypophosphatemia, 201

Neutral stain, of Ehrlich, 759-760

Neutron activation analysis, in nutritional assessment, 336-337

Neutropenia, 879-893
 acquired, 884-888
 age-related, 888-889
 autoimmune, 888-889
 bone marrow recovery and, 889-890
 chronic idiopathic, 885
 constitutional, 882-884
 cyclic, 882-883
 definition of, 880
 drug-induced, 882
 evaluation of, 890-891
 in children, 891
 in pediatric patients, 888-889, 891
 mechanisms causing, 881-882
 severity of, 880
 treatment of, 892

Neutrophil(s), band, counting of. See *Band count*.
 definition of, 895-896
 in urine, 16

Neutrophilia, reactive, 870-875
 causes of, 870-871
 differential diagnosis of, 873-874, 916-917
 hereditary, 871
 in Down syndrome, 874-875
 kinetic mechanisms in, 871-872
 neutrophil morphology in, 872-873
 toxic, 872

Newborn infants. See *Neonates*.

Niacin, assay for, 378

requirements for, in elderly persons, 445-446

Nicotinamide load test, in niacin assay, 378

Nitric oxide radical, as oxidant, 467

Nitrogen balance, in elderly persons, 441-442
 in nutritional assessment, 335, 365-366
 transthyretin in, 360

Nocht stains, 763-764

Nodules, thyroid. See *Thyroid gland, nodular disease of*.

Nonthyroid sickness, free thyroxine levels in, 614-615

Norepinephrine, excess of, in hypertension, 295-297

Normocytic anemia, red cell indices in, 781

Nuclear magnetic resonance, in magnesium determination, 214

Nuclear Regulatory Commission, laboratory regulations of, 741

Nutrients, inadequate availability of, 316
 stability of, during testing, 328

Nutrition. See also *Malnutrition*.
 antioxidants in. See under *Free radicals*.
 deficiencies in, 317
 factors affecting, biologic, 324-325
 drug interactions, 325
 free radicals and. See *Free radicals*.
 immune function and, 457-463
 in elderly persons. See under *Elderly persons*.
 in neonates. See under *Neonates*.

Nutrition Screening Initiative, 437

Nutrition support, 313-522
 complications of, prevention of, 501
 costs of, 500-501
 criteria for, 494-495
 delayed, costs of, 498-499
 failure to provide, consequences of, 494
 in cancer prevention, 472-475
 in metabolic disorders, 409-434
 cofactor-replacement therapy, 427-430
 for detoxification, 430
 formulations for, 430-432
 nutrient prohibition in, 422-427
 nutrient restriction in, 412-422
 inadequate, costs of, 498-499
 monitoring of, 318
 routes for, 499-500
 test panels for, 321-324

Nutritional assessment, 315-329, 331-354
 absorptionmetry in, 336
 analytic considerations in, 328-329
 anthropometry in, 333-334
 bioelectrical impedance in, 337-338
 biologic variables in, 324-325
 body composition measures in, 332-340
 clinical, 344-345
 clinical indications for, 501-502

Nutritional assessment (*Continued*)
 complement system in, 461
 computed tomography in, 336
 confirmatory testing in, 318
 delayed hypersensitivity in, 340-341,
 345-346, 461
 financial implications model for, 502-504
 functional tests in, 318, 340-343
 global, 343-345, 496-497
 global testing in, 496-497
 goals of, 319-324
 immune function evaluation in, 340-341,
 460-462
 in elderly persons, 325, 348, 436-438
 in nutritional therapy monitoring, 318
 indications for, 501-502
 infrared interactance in, 336
 isotope techniques in, 335
 leukocyte terminal deoxynucleotidyl
 transferase determination in, 461
 magnetic resonance imaging in, 336
 multivariable equations for, 345-346
 muscle function evaluation in, 341-343
 neutron activation analysis in, 336-337
 nitrogen balance in, 335
 potassium content in, 337
 predictive value of, 345-348
 prognostic nutritional index in, 320
 proteins in, 355-371
 albumin, 338-339, 345-346, 356-357
 C-reactive, 366
 fibronectin, 339-340, 364-365
 interleukins, 366-367
 nitrogen balance and, 365-366
 retinol-binding, 360-362
 somatomedin C, 362-364
 transferrin, 339, 345-346, 357-358
 transthyretin, 339, 359-360
 visceral, 338-340
 reflexive testing in, 497-499
 result interpretation in, 324-329
 screening program for, 504-505
 screening programs in, 319, 437-438,
 504-505
 skinfold thickness in, 336, 345-346
 specimen contamination in, 328
 static tests in, 318, 328-329
 subjective, 320
 test panels in, 321-324
 tests for, 317-319
 thymulin in, 462
 timeliness of, 495-496
 total body conductivity in, 337
 trace metal assays in, 382-384
 ultrasound in, 335-336
 underutilization of, 320-321
 urine testing in, 335
 vitamin assays in, 373-381
 fat-soluble, 379-381
 water-soluble, 374-379
 weight measurement in, 332-333

Occupational Safety and Health Act,
 laboratory regulations of, 741-742
 Oncogenous phosphaturia, 196
 Ophthalmopathy, Graves', computed
 tomography of, 721
 Organic osmolytes, 141-142
 Orthoiodohippurate, labeled in kidney
 function assessment, 62-64
 Osmolality, sodium balance and, 136
 Osmoles, idiogenic, 141-142
 Osmolytes, organic, 141-142
 Osmometry, in urinalysis, 132
 Osteomalacia, oncogenic, 196
 Osteoporosis, nutritional support in, 442
 Oxalate crystals, in urine, 18
 Oxidation, in carcinogenesis, 472-475
 of low-density lipoproteins, in atherosclerosis, 475-480
 Oxidative stress, cellular damage in, 468
 Oxygen, free radical forms of, 466-468

Pancreatitis, hypocalcemia in, 165
 lymphocytopenia in, 928
 Papillary thyroid carcinoma, 726
 fine-needle aspiration in, 702
 prognosis for, 729-730
 treatment of, 730
 Para-aminohippurate, clearance of, 34-38
 in elderly persons, 272
 tubular secretion of, 48
 Paralysis, familial hyperkalemic periodic, 152
 Parathyroid hormone, deficiency of. See
 Hypoparathyroidism.
 determination of, 159-160
 excess of. See *Hyperparathyroidism*.
 in calcium homeostasis, 157-158
 Parenteral nutrition, hypophosphatemia in, 199
 transition from, transthyretin levels in, 360
 types of, 500
 Pareto diagram, in quality management, 522
 Pathology assistants, regulations on, 992-993
 Pediatric patients. See also *Neonates*.
 fever in, band count in, 898
 hypercalcemia in, 174-175
 kidney function in, assessment of, 257-267
 neutropenia in, 888-889, 891

nutrition in, 389-408
 assessment of, somatomedin levels in, 363-364
 phenylketonuria in. *See Phenylketonuria.*
 potassium regulation in, 261-262
 sodium regulation in, 260-261
 urine concentration ability in, 260
 Pentagastrin test, in thyroid cancer, 731-732
 Peripheral smear review, 853-861
 adaptation to other laboratories, 858
 benefits of, 858-861
 cost of, 858
 definition of, 854
 performance of, 855-857
 personnel for, 857
 time required for, 857-858
 tools for, 854-855
 turnaround time for, 857
 Peroxidation, 467
 Personnel, for laboratories, requirements for, 990-991
 standards for, 745-747
 pH, conversion to hydrogen ion, 107-108
 of urine, 14
 in renal tubular acidosis, 119-120
 Phagocytosis, in malnutrition, 459-460
 Phenobarital, hypocalcemia from, 165
 Phenolsulfonphthalein test, in renal plasma flow determination, 274
 Phenyl-Free formula, in phenylketonuria, 419-422
 Phenylketonuria, differential diagnosis of, 418
 historical aspects of, 410
 nutrition support in, 412, 414, 417-422, 431
 pathophysiology of, 417-418
 screening for, 411
 Pheochromocytoma, hypercalcemia in, 171-172
 hypertension in, 295-297
 Phosphate, determination of, 183-184
 imbalance of, 183-207
 hyperphosphatemia, 165-166, 184-192
 hypophosphatemia, 187, 192-204
 in neonatal nutrition, 394-395
 Phosphate binders, in hyperphosphatemia, 191-192
 Phosphaturia, oncogenous, 196
 Phosphomolybdate, in phosphate determination, 183
 Phosphosoda, in hypophosphatemia, 203
 Phylloquinone assay, 381
 Phytohemagglutinin, in lymphocyte function testing, 341
 Pitressin, in diabetes insipidus, 147
 Pituitary-thyroid axis, free thyroxine-thyrotropin relationships and, 660-661
 thyrotropin production and, 674-676
 Plasma ascorbic acid assay, 378-379
 Plasma cell dyscrasias, diagnosis of, flow cytometry in, 842
 Plasma creatinine, 35-44
 vs. glomerular filtration rate, 42-43
 Plasminogen, assays for, 953
 Platelet(s), age of, volume of, 938-939
 evaluation of, flow cytometry in, 846
 function of, evaluation of, 953-954
 in liver disease, 959
 mean volume of. *See Mean platelet volume.*
 Platelet count, in disseminated intravascular coagulation, 957
 instruments for, 820
 vs. platelet volume, 940-941
 Plehn stains, 762
 Polychrome methylene blue stains, 764-766, 906-907
 Polyethylene glycol precipitation, in immune complex measurement, 71
 Polymyalgia rheumatica, erythrocyte sedimentation rate in, 794-795
 Porphyria, nutrition support in, 415-416
 thyroxine-binding globulin levels in, 589
 Pors-Nielson method, for glomerular filtration rate determination, 60-61
 Potassium, determination of, in hypertension, 288-289
 distribution of, abnormal, 151-152
 imbalance of, 149-156
 hyperkalemia, 149-153
 hypokalemia, 153-155, 293-294
 regulation of, in pediatric patients, 261-262
 total body, in nutritional assessment, 337
 tubular secretion of, 150
 Potassium chloride, in hypokalemia, 154-155
 Potassium phosphate, in hypophosphatemia, 203-204
 Prealbumin (transthyretin), in nutritional assessment, 339, 359-360
 Pregnancy, free thyroxine levels in, 611-612
 galactosemia in, 425
 glomerular filtration rate in, 38
 inborn metabolic disorders in, 411-412
 thyroxine-binding globulin levels in, 588
 Premature infants, nutrition in, 389-408
 carbohydrates, 393-394
 electrolytes, 390-391
 fluids, 390-391
 lipids, 392-393
 minerals, 394-399
 protein, 391-392
 vitamins, 399-404
 Prematurity, anemia of, 395-396

Probucol, in atherogenesis prevention, 478–479

Proficiency testing, 521
in hematology, 973–985
for unregulated analytes, 975
guidelines for, 975–983
optimum performance conditions for, 979–980
postanalytic activities in, 980
preanalytic aspects of, 975–979
regulations for, 974–975
report review in, 980–983
unacceptable results in, response to, 983
unsatisfactory scores in, 974–975
unsuccessful scores in, 975
regulations on, 974–975, 991–992
requirements for, 747–749

Prognostic nutritional index, 320, 345

Project management tools, for quality control, 522–523

Proliferation defects, neutropenia in, 881

Propionic acidemia, carnitine in, 430

Prostaglandins, estimation of, 244–245
in kidney function, 241–245

Prostate gland, status of, 279–286
prostate specific antigen in, 284–285
prostatic acid phosphatase in, 279–284

Prostate specific antigen, determination of, 284–285

Prostatectomy, irrigation after,
hyponatremia in, 139

Prostatic acid phosphatase, determination of, 279–284

Protein(s), deficiency of, assessment of. See *Nutritional assessment, proteins in*
electrophoresis of, in immune complex measurement, 70
for thyroid hormone transport. See *Thyroid hormone(s), transport proteins for*
in geriatric nutrition, 441–442
in milk, 391–392
in neonatal nutrition, 391–392
in nutritional assessment. See under *Nutritional assessment*.
in urine. See *Proteinuria; Urine, protein in*.

Protein C, assays for, 952–953
deficiency of, 965–966

Protein S, assays for, 952–953
deficiency of, 965–967

Proteinuria, 21–31
detection of, 22–26
in nephrotic syndrome, 27–30
in non-nephrotic range, 26–27
isolated, 26–27
orthostatic (postural), 26–27
pathogenesis of, 21–22
transient, 26–27
with normal renal function, 26–27

Prothrombin time, in disseminated intravascular coagulation, 957
in liver disease, 960
with lupus anticoagulant, 962

Protirelin, 674

Prussian blue stain, for iron, 908–910

Pseudohyperkalemia, 149

Pseudohypoaldosteronism, 151

Pseudohyponatremia, 137

Pseudohypoparathyroidism, 162, 189

Pseudopseudohypoparathyroidism, 162

Pseudovitamin D deficiency, 400

Psychiatric disorders, thyrotropin measurements in, 678

Pterin profile, in phenylketonuria, 418

Public Law 100–587. See *Regulatory and legislative issues, Clinical Laboratory Improvement Amendments of 1988*.

Pulse radiolysis, in free radical measurement, 471

Purine nucleoside phosphorylase deficiency, lymphocytopenia in, 926

2-Pyridone, in niacin assay, 378

Pyridoxal 5-phosphate test, in vitamin assay, 376

Pyridoxine. See *Vitamin B₆*.

Pyruvate metabolic disease, nutrition support in, 413

Quality management, 513–514, 515–524
clinical pathologist attributes and, 516–517
community concept of, 518
computers in, 521
cycle times and, 520–521
definitions in, 517–518
education for, 518–519
implementation of, 519
in flow cytometry, 847–848
in hematologic testing, red cell indices in, 776–777
in hematology, 976–977
literature on, 523–524
of erythrocyte sedimentation rate method, 793

of hematologic instruments, 826–827

peripheral smear review in, 853–861

philosophy of, 515–516

planning for, 519

proficiency testing in, 521

regulations on, 744–745, 989–990

statistical quality control in, 519–520

statistical tools for, 522–523

Radioassay, for folic acid, 377

Radioimmunoassay, for DNA antibodies, 74
 for free thyroxine, 615, 654
 for kallikrein-kinin system activity, 240–241
 for prostaglandins, 245
 for prostatic acid phosphatase, 281–283
 for thyroxine-binding globulin, 594

Radioisotope methods, for kidney function assessment, 44–45, 53–68
 agents for, 55–57, 62
 compartmental analysis in, 57
 effective renal plasma flow, 61–64
 external imaging methods in, 60–61, 63–64
 glomerular filtration rate, 53–61
 sampling methods for, 57, 59–60
 for thyroid gland evaluation, 711–714, 728

Radiotherapy, in thyroid cancer, 730
 lymphocytopenia in, 927

Raji-cell assay, for immune complexes, 72–73

Rapid slide tests, in infectious mononucleosis, 865–866

Receptors, thyroid hormone. See *Thyroid hormone receptor(s)*.

Red cell(s). See also *Erythrocyte(s)*.

Red cell distribution width, 776
 in anemia differential diagnosis, 777–781

Red cell indices, 773–785
 automated analysis of, 775–776
 derivation of, 774
 history of, 773
 in anemia differential diagnosis, 777–781
 in complete blood count enhancement, 781–782
 in system longitudinal process control, 776–777

Red cell survival, measurement of, flow cytometry in, 847

Red cell volume, measurement of, flow cytometry in, 847

Regulatory and legislative issues, 739–752
 Clinical Laboratory Improvement Act of 1967, 740–741
 Clinical Laboratory Improvement Amendments of 1988, 987–994
 accreditation in, 988–989
 advisory committee for, 750–751
 complexity model in, 744–745
 controversy in, 993
 corrections to, 751
 cytology in, 989
 deemed organizations in, 989
 events leading to, 742–743
 evolution of, 993
 exemptions from, 989
 inspections in, 988–989

laboratory defined in, 743–744
 pathology assistants in, 992–993
 personnel standards in, 745–747, 990–991
 proficiency testing in, 747–749, 991–992
 quality control in, 749–750, 989–990
 sanctions in, 987–988
 test management in, 750
 waived testing in, 744–745
 workload restrictions in, 989–990

Department of Health and Human Services in, 741

Food and Drug Administration in, 741
 hematology instruments, 818–819
 history of, 739–744

Interstate Quarantine Regulations in, 742

Medicare as, 739–740

Nuclear Regulatory Commission in, 741

Occupational Safety and Health Act in, 741–742

Resource Conservation and Recovery Act in, 742

Relative dose-response test, in vitamin A assay, 380

Renal function, 1–302

Renal plasma flow. See also *Effective renal plasma flow*.
 measurement of, 33–36

Renal reserve, 37

Renal tubular acidosis, 117–129
 acid loading tests in, 121–122
 ammonium chloride loading test in, 121–122
 arginine hydrochloride loading test in, 122
 bicarbonate titration in, 124–125
 buffer loading tests in, 124–126
 calcium chloride loading test in, 122
 diagnosis of, clinical approach to, 126–128
 distal, 117–119
 furosemide test in, 124
 hypocalcemia in, 166
 net acid excretion in, 120
 proximal, 117–119
 sodium sulfate infusion test in, 123
 urinary acidification tests in, 121–126
 urinary anion gap in, 120–121
 urine carbon dioxide partial pressure in, with phosphate infusion, 126
 with urinary alkalinization, 125–126
 urine pH in, 119–120

Renin, in renal function, 8
 tumor secreting, hypertension in, 299

Renovascular hypertension, 297–299

Resistance, to thyroid hormones. See under *Thyroid hormone(s)*.

Resource Conservation and Recovery Act, laboratory regulations of, 742

Respiration, in acid-base regulation, 105
 Respiratory acidosis, diagnosis of, 113
 in mixed acid-base disorders, 114
 potassium redistribution in, 152
 Respiratory alkalosis. See under *Alkalosis*.
 Resting energy expenditure, in elderly persons, 439, 441
 Reticular dysgenesis, neutropenia in, 882
 Reticulated platelets, flow cytometry studies in, 846
 Reticulocyte(s), flow cytometry studies of, 847
 Reticulocyte count, instruments for, 823–824
 stains for, 907–908
 Retinoid X receptor, 534
 Retinol (vitamin A), assay for, 379–380
 in geriatric nutrition, 448–449
 in neonatal nutrition, 399–400
 Retinol-binding protein, complex with transthyretin, 359–361
 in nutritional assessment, 360–362
 Retinyl esters, in elderly persons, 448–449
 in vitamin A assay, 380
 Reuter stains, 765
 Rhabdomyolysis, hyperkalemia in, 152
 hyperphosphatemia in, 185–187
 hypophosphatemia in, 201
 Rheumatoid arthritis, erythrocyte sedimentation rate in, 794–795
 neutrophilia in, 871
 Rh-negative cells, detection of, flow cytometry in, 847
 Riboflavin (vitamin B₂), assay for, 374–375
 in geriatric nutrition, 445–446
 in metabolic disease, 428
 in neonatal nutrition, 402–403
 Rickets, in vitamin D deficiency, 400–401
 vitamin D-dependent, hypocalcemia in, 164–165
 Roe stains, 766
 Romanowsky stains, 763
 Romanowsky-Giemsa effect, 766–768
 Run charts, in quality management, 523

Saline solution, hypertonic, in
 hyperkalemia, 152
 in hypercalcemia, 176
 Sapirstein model, for compartmental analysis, in kidney function assessment, 57
 Sarcoidosis, hypercalcemia in, 173–174
 lymphocytopenia in, 928
 Scatter diagrams, in quality management, 523
 Schilling test, in vitamin B₁₂ assay, 377

Schwachman-Diamond syndrome, neutropenia in, 882
 Screening programs. See also *Wellness testing*.
 for inborn metabolic disorders, 411–412
 for nutritional assessment, 319, 437–438
 Seabright Bantam syndrome, 564
 Sebastiani syndrome, mean platelet volume in, 945
 Sediment, urinary, analysis of, 16–18
 in kidney failure, 93–94
 Sedimentation ratio, Zeta, 792
 Selenium, as antioxidant, 474
 determination of, in nutritional assessment, 383–384
 in atherogenesis prevention, 480
 in geriatric nutrition, 444–445
 in neonatal nutrition, 398
 Self-tolerance, autoimmune disease and, 683–685
 Senescence, anemia of, 444
 Sepsis, band count in, 898
 mean platelet volume in, 944
 Serologic tests, in infectious mononucleosis, 865–866
 Serology, in kidney function evaluation, 69–87
 Severe combined immunodeficiency, lymphocytopenia in, 925–926
 Sickle cell disease and trait, hemoglobin analysis in, 803–804, 806, 808–809, 811
 hyperphosphatemia in, 189
 Silicon, requirements of, in elderly persons, 445
 Sipple's syndrome, hypercalcemia in, 170
 Skin testing, in nutritional assessment, 340–341
 Skinfold thickness, in nutritional assessment, 333–334, 336, 345–346
 Smear, peripheral, review of. See *Peripheral smear review*.
 Smoking, in atherogenesis, 479–480
 Snake bite, lymphocytopenia in, 928
 Sodium, balance of, 135–136
 distribution of, 135–136
 excretion of, in kidney failure, 94–97
 imbalance of, 135–148
 hypernatremia, 142–147
 hyponatremia, 136–142, 261
 vs. normal sodium-water balance, 135–136
 regulation of, in pediatric patients, 260–261
 Sodium bicarbonate, in hyperkalemia, 152
 Sodium sulfate infusion test, in renal tubular acidosis, 123
 Somatotropin, in nutritional assessment, 362–364
 Southeast Iowa Wellness Program, 483–492

Specific gravity, of urine, 14, 132

Splenectomy, in neutropenia, 892

mean platelet volume in, 946

Stains, in flow cytometry, 835

in hematologic testing, 759-771, 905-921

- brilliant cresyl blue, 912-913
- Chenzinsky, 760-762
- Ehrlich, 759-760
- eosin, 906-907
- fluorescent, 919
- for Heinz body preparation, 912-913
- for iron, 908-910
- for leukocyte alkaline phosphatase score, 916-917
- for leukocyte esterase, 917-918
- for myeloperoxidase, 913-914
- for reticulocyte enumeration, 907-908
- for tartrate-resistant acid phosphatase, 918-919
- Giems, 765-766, 906-907
- Grünwald, 764-765
- history of, 759-760
- immunocytochemical, 919
- in leukemia, 913-914
- Jenner, 764-765
- Leishman, 765
- Lillie, 766
- Malachowski, 762-763
- May, 764-765
- methyl violet, 912-913
- methyle blue, 906-908
- Nocht, 763-764
- Plehn, 762
- Prussian blue, 908-910
- Reuter, 765
- Roe, 766
- Romanowsky, 763
- Romanowsky-Giemsa effect and, 766-768
- Sudan black B, 915-916
- Wilcox, 766
- Wright, 765, 906-907

Stones, kidney. See *Nephrolithiasis*.

Streptococcal infection, glomerulonephritis after, 81-82

Stroke, mean platelet volume in, 947

Sudan black B stain, 915-916

Superoxide dismutase, as free radical scavenger, 466, 468-469

Superoxide radical, 466-468

Syndrome of inappropriate antidiuretic hormone secretion, hyponatremia in, 138, 142

Systemic lupus erythematosus, circulating anticoagulants in, 962-964

lymphocytopenia in, 926-927

T lymphocytes, flow cytometry studies of, 836-838

- in immunodeficiency, 845
- in leukemia, 839, 841
- in autoimmune thyroid disease, 683-685, 687
- reduction of, in malnutrition, 459

Tamm-Horsfall protein, 17-18

Tartrate-resistant acid phosphatase, detection of, 918-919

Technetium 99m compounds, in kidney function assessment, 56-57, 62-63

in thyroid imaging, 711, 713

Temporal arteritis, erythrocyte sedimentation rate in, 794-795

Test management, regulations on, 750

Test panels, for nutritional assessment, 321-324

Tetany, in hyperphosphatemia, 190

- in hypocalcemia, 166

Tetrahydrobiopterin, in metabolic disease, 428

- in phenylketonuria, 417-418

Thalassemias. See also *Hemoglobinopathies*.

- hemoglobin composition in, 802-803
- hemoglobin quantitation in, 806, 808
- red cell indices in, 777-781

Thallium 201, in thyroid imaging, 711, 714

Theophylline therapy, hypercalcemia in, 171

Thiamin. See *Vitamin B₁*.

Thiazin stains, 761, 765-766

Thiobarbituric acid-reactive substances, in free radical measurement, 472

Thionin stain, 760

Thirst, decreased, hypernatremia in, 142, 144

Thrombocytopenia, congenital, mean platelet volume in, 945-946

- flow cytometry studies in, 846
- mean platelet volume in, 944-945

Thrombocytosis, from infant formulas, 393

- mean platelet volume in, 945

Thrombosis, in disseminated intravascular coagulation, 956-959

Thromboxanes, in kidney function, 241-244

Thymulin, in nutritional assessment, 462

Thyroglobulin, antibodies to, 685-686

- in simple goiter, 690
- in thyroid atrophy, 690
- determination of, in thyroid cancer, 728, 731-732

Thyroid disease, pathophysiology of, 531-752

Thyroid function testing, automation of, 631-644

- immunoassays for, accuracy of, 639-641
- data management for, 633-634
- disadvantages of, 635
- future trends in, 643

T₄. See *Thyroxine*.

Thyroid function testing (Continued)

- lot-to-lot variation in, 641–642
- method comparison in, 642
- performance evaluation in, 642–643
- precision of, 638
- reagent stability in, 633
- sample management for, 634
- sensitivity of, 638–639
- signal detection in, 634–635
- systems for, 635–638
- type of, 632–633

for congenital hypothyroidism, 645–652

transport protein variations effects on, 592–593

Thyroid gland, atrophy of, 690

- autoimmune disease of, 683–697
- cancer of. See under *Cancer*.
- computed tomography of, 719–722
- diffuse disease of, ultrasonography of, 718
- disease of, mean platelet volume in, 944
- fine-needle aspiration of, 699–709
- imaging for, 716–719
- in cancer diagnosis, 728–729
- ultrasonographic guidance of, 716–719

imaging of, 711–724

- computed tomography in, 719–722
- for fine-needle aspiration, 716–719
- magnetic resonance in, 722–723
- nuclear techniques in, 711–714
- ultrasound in, 714–719

magnetic resonance imaging of, 722–723

nodular disease of, computed tomography of, 720

- fine-needle aspiration in, 701
- ultrasonography of, 716, 718–719
- versus cancer, 725

nuclear medicine imaging of, 711–714

physical examination of, 727

ultrasonography of, 714–719

Thyroid growth-stimulating antibodies, in Hashimoto's thyroiditis, 689

Thyroid hormone(s). See also *Thyroxine*.

- determination of, transport protein variations effects on, 592–593
- in thyroid cancer, 727–728
- mechanism of action of, 531–541, 543–561
- at developmental level, 555–556
- central hypothesis for, 531–532
- coordinate, 552–554
- DNA interactions in, 533–535
- gene expression in, 535–536
- historical review of, 543–546
- lipogenesis and lipolysis and, 553–554
- nontranscriptional, 536–538
- nutritional influences on, 552–553
- receptors in. See *Thyroid hormone receptor(s)*.

thyroid hormone response elements in, 532–533, 535, 550–552

transcription initiation in, 536

resistance to, 563–581

- classification of, 564–565
- clinical features of, 566–567
- diagnosis of, 567–571
- etiology of, 571–575
- generalized tissue, 564
- inheritance of, 565–566
- pathophysiology of, 575–577
- peripheral tissue, 565
- pituitary, 564
- prevalence of, 565
- tissue changes in, 569–571
- treatment of, 577

transport proteins for, 583–598

- abnormalities of, detection of, 594–595
- dissociation of, 603–604
- dynamic equilibrium of, 601
- hormone distribution and, 600
- physicochemical properties of, 584–586
- variations in, 586–592
- thyroid function tests affected by, 592–593

Thyroid hormone auxiliary proteins, 548

Thyroid hormone receptor(s),

- developmental functions of, 555–556
- DNA interactions of, 533–535
- historical review of, 543–546
- in gene expression, 535–536
- in transcription initiation, 536
- molecular biology of, 546–550
- mutation of, hormone resistance in, 571–577
- tissue distribution of, 548–550

Thyroid hormone receptor auxiliary proteins, 533–534

Thyroid hormone response elements, 532–533, 535, 550–552

- in hormone resistance, 571, 575–576

Thyroid-associated lymphoid tissue, in autoimmune disease, 687

Thyroidectomy, in thyroid cancer, 730–731

Thyroiditis, Hashimoto's, autoantibodies in, 689–690

- fine-needle aspiration in, 701
- subacute, fine-needle aspiration in, 701
- ultrasonography of, 718

Thyroid-stimulating antibodies, in Graves' disease, 687–689

Thyroperoxidase, autoantibodies to, 686

- in thyroid atrophy, 690
- in thyroiditis, 689–690

Thyrotocisis, hyperphosphatemia in, 189

Thyrotropin, levels of, versus free thyroxine levels, 660–670

measurement of, 673–682

algorithm for, in thyroid disease, 680–681
 analytic considerations in, 676–677
 elevated values from, significance of, 679
 in congenital hypothyroidism screening, 646–648
 in epilepsy, 678–679
 in psychiatric disorders, 678
 in thyroxine replacement therapy, 677–678
 in thyroxine suppressive therapy, 678
 pituitary function and, 674–676
 sensitivity of, 673–674
 terminology of, 673–674
 suppression of, monitoring in, 678

Thyrotropin receptor, autoantibodies to, 686
 in Graves' disease, 687–689

Thyrotropin-binding immunoglobulin G, 687

Thyrotropin-releasing hormone stimulating test, 674–675

Thyroxine, determination of, in congenital hypothyroidism screening, 646–648 free, 599–629
 capillary penetration by, 606–611
 equilibrium of, with bound state, 600–601
 hypothesis concerning, 599–612
 basic concepts of, 599–603
 physicochemical basis of, 603–606
 physicochemical effects of, 606–611
 physiologic effects of, 611–612
 in pregnancy, 611–612
 measurement of, 612–625, 653–672
 dialysis techniques for, 613–615, 654–656, 663–667
 immunoassays in, 615–625
 in nonthyroidal disorders, 657–658
 in thyroidal disorders, 658–659
 in vivo, 656–657
 methods for, 654–656
 normal physiology and, 653–654
 radioimmunoassay, 615, 656
 radioimmunoassay/dialysis in, 615
 thyrotropin levels and, 660–670
 ultrafiltration in, 613–615

replacement therapy with, in congenital hypothyroidism, 650
 thyrotropin monitoring in, 677–678
 suppressive therapy with, in thyroid cancer diagnosis, 728
 thyrotropin monitoring in, 678

Thyroxine-binding globulin, abnormalities of, detection of, 594
 deficiency of, 586
 free hormone hypothesis and, 600
 physicochemical properties of, 584–585
 variations in, 586–589, 592–593

Thyroxine-binding prealbumin (transthyretin), in nutritional assessment, 339, 359–360

TNM classification, of thyroid cancer, 726–727

α-Tocopherol. See *Vitamin E*.

Total body conductivity, in nutritional assessment, 337

Total lymphocyte count, in nutritional assessment, 341

Total radical-trapping antioxidant parameter method, in free radical measurement, 472

Total renal plasma flow, calculation of, 35

Toxic shock syndrome, hypocalcemia in, 166

Toxoplasmosis, lymphocytosis in, 867

Trace metal assays, in nutritional assessment, 382–384

Trade-off hypothesis, in renal failure, 190–191

Transferrin, in nutritional assessment, 339, 345–346, 357–358

Transplantation, kidney, hypophosphatemia after, 194

Transport maximum, in renal tubules, 47–48

Transport proteins, for thyroid hormones. See *Thyroid hormone(s), transport proteins for*.

Transthyretin, abnormalities of, detection of, 594–595
 free hormone hypothesis and, 600
 in nutritional assessment, 339, 359–360
 physicochemical properties of, 585–586
 variations in, 589–593

TRAP (total radical-trapping antioxidant parameter) method, in free radical measurement, 472

Triacid stain, 760

Triene:tetraene ratio, in essential fatty acid deficiency, 392–393

Triglycerides, determination of, in hypertension, 290–291
 in neonatal nutrition, 392–393
 medium-chain, in infant formulas, 393

Triple phosphate crystals, in urine, 18

Tryptophan load test, in niacin assay, 378
 in vitamin assay, 376

TSH. See *Thyrotropin*.

Tuberculosis, lymphocytopenia in, 927

Tubules, renal. See *Kidney, tubules of*.

Tumor lysis syndrome, hyperphosphatemia in, 187–188

Tumor markers, in thyroid cancer, 728

Tumor necrosis factor, lymphocytopenia from, 928

Tumoral calcinosis, hyperphosphatemic, 189

Turnaround times, in laboratory testing, 520-521

Tyrosinemia, nutrition support in, 415

Ulcerative colitis, lymphocytopenia in, 928

Ultrafiltration, in free thyroxine measurement, 613-615

Ultrasoundography, in nutritional assessment, 335-336

- of thyroid, 714-719, 728
- for fine-needle aspiration, 716-719

Unna's polychrome methylene blue stains, 764

Unstable hemoglobin screen, in hemoglobinopathies, 809

Urea, determination of, 44, 55

Urea cycle disease, nutrition support in, 415, 430

Uremia, clinical signs of, 99

- creatinine in, 41-42
- hyperphosphatemia in, 190

Uric acid, determination of, in hypertension, 291

- in urine, 18

Uridyltransferase activity test, in galactosemia, 425

Urinalysis, 13-20

- chemical, 14-16
- in hypertension, 291
- in kidney failure, 93-94
- in nephrolithiasis, 228-229
- macroscopic, 14-16

Urinary acidification tests, in renal tubular acidosis, 121-126

Urinary sediment, analysis of, 16-18

- in kidney failure, 93-94

Urinary tract, obstruction of, kidney injury in, 263-264

Urine, albumin in, 14-15

- analysis of, in nutritional assessment, 335
- anion gap in, in renal tubular acidosis, 120-121
- Bence Jones proteins in, 15-16
- carbon dioxide partial pressure of, with alkalinization, 125-126
- casts in, 17-18, 93
- colligative properties of, 132
- concentration of, 131-134

 - in elderly persons, 274-275
 - in pediatric patients, 260

- crystals in, 18
- dilution of, 131-134

 - in elderly persons, 275
 - inadequate, hyponatremia in, 137-138

- enzymes in, 15

flow of, in kidney failure diagnosis, 92-93

kallikreins in, 238-239, 241

net charge of, in renal tubular acidosis, 120-121

osmometry of, 132

pH of, 14

- in renal tubular acidosis, 119-120

protein in. See also *Proteinuria*

- low-molecular-weight, 15
- Tamm-Horsfall, 17-18

specific gravity of, 14, 132

Vasculitis, with glomerulitis, diagnosis of, 92

Ves-Matic System, for erythrocyte sedimentation rate, 792

Viral infections, lymphocytosis in, 867

Visceral proteins, in nutritional assessment, 338-340, 355-371

Vitamin(s), as antioxidants, 470-471

- assays of, in nutritional assessment, 373-381
- in geriatric nutrition, 445-451
- in metabolic diseases, 427-430
- in neonatal nutrition, 399-404

Vitamin A (retinol), assay for, 379-380

- in geriatric nutrition, 448-449
- in neonatal nutrition, 399-400

Vitamin B₁ (thiamin), assay for, 374-375

- in geriatric nutrition, 445-446
- in metabolic disease, 428
- in neonatal nutrition, 402

Vitamin B₂ (riboflavin), assay for, 374-375

- in geriatric nutrition, 445-446
- in metabolic disease, 428
- in neonatal nutrition, 402-403

Vitamin B₆ (pyridoxine), assay for, 374, 376

- in geriatric nutrition, 446
- in metabolic disease, 427-428
- in neonatal nutrition, 403

Vitamin B₁₂ (cyanocobalamin), assay for, 377

- in geriatric nutrition, 446-447
- in metabolic disease, 427-428
- in neonatal nutrition, 404

Vitamin C (ascorbic acid), as antioxidant, 470-471, 474-475

- assay for, 378-379
- in atherogenesis prevention, 479-480
- in geriatric nutrition, 447-448
- in neonatal nutrition, 403-404

Vitamin D, assay for, 381

- disorders of, hypocalcemia in, 163-165
- in geriatric nutrition, 449
- in metabolic disease, 428
- in neonatal nutrition, 400-401

intoxication with, hypercalcemia in, 173
supplementation with, in hypocalcemia, 167-168

Vitamin D₃, synthesis of, in kidney, 10

Vitamin E, as antioxidant, 470-471, 474-475
assay for, 380-381
in atherogenesis prevention, 479
in geriatric nutrition, 450
in metabolic disease, 428
in neonatal nutrition, 401-402

Vitamin K, assay for, 381
deficiency of, in liver disease, 957
in geriatric nutrition, 450-451
in neonatal nutrition, 402

von Willebrand's disease, 952-954

Waist circumference, in nutritional assessment, 334

Water, body, sodium balance and, 135-136

Water intoxication, isotonic, in
hypernatremia, 146

Water load test, for kidney diluting capacity, 133

Wegener's granulomatosis, antineutrophil cytoplasmic antibodies in, 79-81

Weight measurement, in nutritional assessment, 332-333

Wellness testing, 483-492
benefits of, 489-490
for hypercholesterolemia, 487-489
for iron deficiency, 486-487
ubiquity of, 483-484

Werner's syndrome, hypercalcemia in, 170

Westergren erythrocyte sedimentation rate method, 787-788, 792

Whipple's disease, lymphocytopenia in, 928

Whooping cough, lymphocytosis in, 867-868

Wilcox stains, 766

William's syndrome, hypercalcemia in, 174-175

Williams-Beuren syndrome, 400-401

Wilson's disease, 398

Wintrobe method, for erythrocyte sedimentation rate, 791-792

Wiskott-Aldrich syndrome, lymphocytopenia in, 927
mean platelet volume in, 945-946

Work of breathing, measurement of, 343

Wright stains, 765, 906-907

X-ray diffraction, in kidney stone analysis, 229

Yttrium-169 compounds, in kidney function assessment, 56

Zeta hematocrit, 792

Zeta sedimentation ratio, 792

Zetafuge method, for erythrocyte sedimentation rate, 791-792

Zinc, deficiency of, lymphocytopenia in, 926
determination of, in nutritional assessment, 382
in geriatric nutrition, 444-445
in neonatal nutrition, 396-397

